The Feasibility of a Prophylactic Mastectomy by Axillary Incision

2012 ◽  
Vol 1 (2) ◽  
Author(s):  
Angelo Matthes ◽  
Gustavo Zucca Matthes
Keyword(s):  
Prophylactic Mastectomy ◽  
Axillary Incision

Prophylactic Mastectomy Lowers Risk of Breast Cancer 90%

Ob Gyn News ◽  
2005 ◽  
Vol 40 (6) ◽  
pp. 17
Author(s):  
BRUCE JANCIN
Keyword(s):  
Breast Cancer ◽  
Prophylactic Mastectomy

Prophylactic Mastectomy - Evaluation and Treatment of High Risk Patients

Swiss Surgery ◽  
2002 ◽  
Vol 8 (2) ◽  
pp. 45-52 ◽  
Author(s):  
Remmel ◽  
Harder
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Prophylactic Mastectomy ◽  
Interdisciplinary Approach ◽  
Reconstructive Procedures ◽  
Medline Search ◽  
Breast Cancer Risk Reduction ◽  
Cancer Risk Reduction

Prophylactic mastectomy is an aggressive strategy for breast cancer risk reduction. The indications and efficiency of this procedures are not yet clearly defined. Randomized, prospective studies, comparing different surgical procedures with other modalities of breast cancer risk reduction are lacking. The report evaluates the existing controversy, based on Medline search in the following sequence: risk factors, possibilities of risk reduction, effectiveness of risk reduction, technical considerations and recommendations. Patient selection is difficult and needs an interdisciplinary approach. The women have to be well informed about all treatment alternatives and various reconstructive procedures. An appropriate risk reduction strategy should be selected individually for each patient. Up to now, there exist only recommendations from different institutions but no definitive guidelines.

Contralateral Prophylactic Mastectomy and Breast Cancer: Clinical and Psychosocial Outcomes

2018 ◽  
Author(s):  
Abenaa Brewster ◽  
Susan Peterson ◽  
Scott Cantor ◽  
Robert Volk ◽  
Yu Shen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prophylactic Mastectomy ◽  
Contralateral Prophylactic Mastectomy ◽  
Psychosocial Outcomes

Issues in Bilateral Prophylactic Mastectomy

2001 ◽  
Vol 9 (1) ◽  
pp. 6-10 ◽  
Author(s):  
Jennifer Dunn Bucholtz ◽  
Amy Strauss Tranin ◽  
Anne T. Mancino ◽  
Ronda Henry-Tillman ◽  
Kent C. Westbrook ◽  
...  
Keyword(s):  
Prophylactic Mastectomy ◽  
Bilateral Prophylactic Mastectomy

scholarly journals Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability

The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. 61-69
Author(s):  
Josien C.C. Scheepens ◽  
Laura van ’t Veer ◽  
Laura Esserman ◽  
Jeff Belkora ◽  
Rita A. Mukhtar
Keyword(s):  
Prophylactic Mastectomy ◽  
Contralateral Prophylactic Mastectomy ◽  
Narrative Review

Is There a Bias Against Obese Patients in the Treatment of Breast Cancer?

2020 ◽  
pp. 000313482098487
Author(s):  
Melinda Wang ◽  
Julian Huang ◽  
Anees B. Chagpar
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Prophylactic Mastectomy ◽  
Implicit Bias ◽  
Treatment Decision ◽  
Obese Patients ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Immediate Reconstruction

Background Patient and tumor characteristics often coincide with obesity, potentially affecting treatment decision-making in obese breast cancer patients. Independent of all of these factors, however, it is unclear whether obesity itself impacts the decision to offer patients undergoing mastectomy breast reconstruction, postmastectomy radiation therapy (PMRT), or neoadjuvant chemotherapy. We sought to determine whether implicit bias against obese breast cancer patients undergoing mastectomy plays a role in their treatment. Methods Medical records of breast cancer patients undergoing mastectomy from January 2010 to April 2018 from a single institution were retrospectively reviewed, separated into obese (BMI ≥30) and nonobese (BMI <30) categories, and compared using nonparametric statistical analyses. Results Of 972 patients, 291 (31.2%) were obese. Obese patients were more likely to have node-positive, triple-negative breast cancers ( P = .026) and were also more likely to have other comorbidities such as a history of smoking ( P = .026), hypertension ( P < .001), and diabetes ( P < .001). Receipt of immediate reconstruction and contralateral prophylactic mastectomy did not vary between obese and nonobese patients. While obese patients were more likely to undergo neoadjuvant chemotherapy (26.5% vs. 18.1%, P = .004) and PMRT (33.0% vs. 23.4%, P = .003), this did not remain significant when controlling for comorbidities and clinicopathologic confounders. Conclusion Obese patients present with more aggressive tumors and often have concomitant comorbidities. Independent of these factors, however, differences in the treatment of patients undergoing mastectomy do not seem to be affected by an implicit bias against obese patients.

Sign in / Sign up

Export Citation Format

Share Document